Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 13, 2009
The FDA requires the use of a Good Manufacturing Practice (GMP) facility for taking stem cell-based therapies into clinical trials. This GMP facility is a clean-room laboratory that ensures the therapeutic products will be safe and contamination-free for patients.
In Spring 2008, CIRM gave $272 million for the construction of twelve stem cell research facilities in California. The University of California, Davis was one of the recipients of this Major Facilities grant. Their $20 million award is supporting construction of the new Institute for Regenerative Cures. This 60,000 square foot building will include a state-of-the-art GMP facility.
Jan Nolta is the director of the UC Davis stem cell program and Institute for Regenerative Cures. Gerhard Bauer is director of the UC Davis GMP laboratory and is an assistant professor at the UC Davis school of medicine.